Sophiris Bio (NASDAQ:SPHS) Upgraded by ValuEngine to “Hold”

Sophiris Bio (NASDAQ:SPHS) was upgraded by equities research analysts at ValuEngine from a “sell” rating to a “hold” rating in a note issued to investors on Tuesday, ValuEngine reports.

Separately, HC Wainwright set a $2.80 price target on shares of Sophiris Bio and gave the company a “buy” rating in a report on Monday, October 21st.

Shares of SPHS opened at $0.37 on Tuesday. The company has a 50-day moving average of $0.47 and a two-hundred day moving average of $0.74. The stock has a market cap of $12.79 million, a price-to-earnings ratio of -0.71 and a beta of 2.80. Sophiris Bio has a one year low of $0.34 and a one year high of $2.19.

An institutional investor recently bought a new position in Sophiris Bio stock. Virtu Financial LLC bought a new position in Sophiris Bio Inc (NASDAQ:SPHS) in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm bought 59,469 shares of the biopharmaceutical company’s stock, valued at approximately $35,000. Virtu Financial LLC owned 0.17% of Sophiris Bio as of its most recent SEC filing. 11.72% of the stock is currently owned by institutional investors.

About Sophiris Bio

Sophiris Bio, Inc, a clinical-stage biopharmaceutical company, focuses on the development of products for the treatment of urological diseases. The company's primary product candidate is PRX302, which is in Phase III clinical trial for treatment of lower urinary tract symptoms of benign prostatic hyperplasia (BPH), as well as for the treatment of localized low to intermediate risk prostate cancer.

Featured Story: Are sell-side analysts objective?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Sophiris Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sophiris Bio and related companies with MarketBeat.com's FREE daily email newsletter.